CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?

Abstract excerpt

Abstract CDK4/6 inhibitors have emerged as a significant advance for the treatment of patients with advanced estrogen receptor–positive breast cancer. However, the identification of predictive markers that optimize their use is proving harder than expected. In this commentary we advocate for unbiased discovery and a collaborative approach across trials. See related article by Finn et al., p. 110

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced Breast Cancer Therapies
• Share to Breast Cancer Treatment Studies
• Share to Cancer-related cognitive impairment studies